Bifogade filer
Medivir (Q3 Review) - New Phase II Study
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
2025-11-07 08:56:00
Redeye comments on Medivir’s Q2 report. A rights issue of cSEK150m was announced, which will fund a new investigator-sponsored trial, smaller than previously but with a control arm. Remetinostat was outlicensed to Biossil for up to USD60m in milestones, a limited deal. We update our base case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/